IGKV2D 40 | ENSG00000251039 | NCBI 28878

Details for: IGKV2D 40

Gene ID: 28878

Symbol: IGKV2D 40

Ensembl ID: ENSG00000251039

Description: immunoglobulin kappa variable 2D-40

Associated with

Adaptive immune system
(R-HSA-1280218)
Anti-inflammatory response favouring leishmania parasite infection
(R-HSA-9662851)
Antigen activates b cell receptor (bcr) leading to generation of second messengers
(R-HSA-983695)
Binding and uptake of ligands by scavenger receptors
(R-HSA-2173782)
Cd22 mediated bcr regulation
(R-HSA-5690714)
Cell surface interactions at the vascular wall
(R-HSA-202733)
Classical antibody-mediated complement activation
(R-HSA-173623)
Complement cascade
(R-HSA-166658)
Creation of c4 and c2 activators
(R-HSA-166786)
Disease
(R-HSA-1643685)
Fc epsilon receptor (fceri) signaling
(R-HSA-2454202)
Fceri mediated ca+2 mobilization
(R-HSA-2871809)
Fceri mediated mapk activation
(R-HSA-2871796)
Fceri mediated nf-kb activation
(R-HSA-2871837)
Fcgamma receptor (fcgr) dependent phagocytosis
(R-HSA-2029480)
Fcgr3a-mediated il10 synthesis
(R-HSA-9664323)
Fcgr3a-mediated phagocytosis
(R-HSA-9664422)
Fcgr activation
(R-HSA-2029481)
Hemostasis
(R-HSA-109582)
Immune system
(R-HSA-168256)
Immunoregulatory interactions between a lymphoid and a non-lymphoid cell
(R-HSA-198933)
Infectious disease
(R-HSA-5663205)
Initial triggering of complement
(R-HSA-166663)
Innate immune system
(R-HSA-168249)
Leishmania infection
(R-HSA-9658195)
Leishmania parasite growth and survival
(R-HSA-9664433)
Leishmania phagocytosis
(R-HSA-9664417)
Parasite infection
(R-HSA-9664407)
Parasitic infection pathways
(R-HSA-9824443)
Potential therapeutics for sars
(R-HSA-9679191)
Regulation of actin dynamics for phagocytic cup formation
(R-HSA-2029482)
Regulation of complement cascade
(R-HSA-977606)
Role of lat2/ntal/lab on calcium mobilization
(R-HSA-2730905)
Role of phospholipids in phagocytosis
(R-HSA-2029485)
Sars-cov infections
(R-HSA-9679506)
Scavenging of heme from plasma
(R-HSA-2168880)
Signaling by the b cell receptor (bcr)
(R-HSA-983705)
Vesicle-mediated transport
(R-HSA-5653656)
Viral infection pathways
(R-HSA-9824446)

Cells (max top 100)

(Marker Scores and respective Thresholds are uniquely calculated using our advanced thresholding algorithms to reveal cell-specific gene markers)

Cell Name: macrophage (CL0000235)
Fold Change: 4.76
Marker Score: 5,294
Cell Name: T cell (CL0000084)
Fold Change: 2.52
Marker Score: 4,338
Cell Name: conventional dendritic cell (CL0000990)
Fold Change: 2.19
Marker Score: 1,512
Cell Name: monocyte (CL0000576)
Fold Change: 1.67
Marker Score: 2,167
Cell Name: granulocyte monocyte progenitor cell (CL0000557)
Fold Change: 1.38
Marker Score: 876
Cell Name: intestinal crypt stem cell of colon (CL0009043)
Fold Change: 1.16
Marker Score: 2,947
Cell Name: goblet cell (CL0000160)
Fold Change: 1.15
Marker Score: 7,653
Cell Name: early T lineage precursor (CL0002425)
Fold Change: 1.05
Marker Score: 802
Cell Name: transit amplifying cell (CL0009010)
Fold Change: 1
Marker Score: 5,679
Cell Name: absorptive cell (CL0000212)
Fold Change: 0.98
Marker Score: 30,361
Cell Name: intestinal epithelial cell (CL0002563)
Fold Change: 0.96
Marker Score: 1,559
Cell Name: abnormal cell (CL0001061)
Fold Change: 0.91
Marker Score: 2,722
Cell Name: neoplastic cell (CL0001063)
Fold Change: 0.87
Marker Score: 5,255
Cell Name: mast cell (CL0000097)
Fold Change: 0.86
Marker Score: 497
Cell Name: brush cell (CL0002204)
Fold Change: 0.78
Marker Score: 708
Cell Name: B cell (CL0000236)
Fold Change: 0.76
Marker Score: 721
Cell Name: myeloid cell (CL0000763)
Fold Change: 0.75
Marker Score: 1,197
Cell Name: fibroblast (CL0000057)
Fold Change: 0.73
Marker Score: 703
Cell Name: neutrophil progenitor cell (CL0000834)
Fold Change: 0.72
Marker Score: 184
Cell Name: intestinal enteroendocrine cell (CL1001516)
Fold Change: 0.69
Marker Score: 550
Cell Name: plasma cell (CL0000786)
Fold Change: 0.64
Marker Score: 714
Cell Name: neutrophil (CL0000775)
Fold Change: 0.63
Marker Score: 383
Cell Name: precursor B cell (CL0000817)
Fold Change: 0.59
Marker Score: 390
Cell Name: common myeloid progenitor (CL0000049)
Fold Change: 0.58
Marker Score: 153
Cell Name: megakaryocyte-erythroid progenitor cell (CL0000050)
Fold Change: 0.57
Marker Score: 238
Cell Name: pro-B cell (CL0000826)
Fold Change: 0.5
Marker Score: 481
Cell Name: megakaryocyte (CL0000556)
Fold Change: 0.42
Marker Score: 240
Cell Name: endothelial cell (CL0000115)
Fold Change: 0.42
Marker Score: 376
Cell Name: fraction A pre-pro B cell (CL0002045)
Fold Change: 0.37
Marker Score: 377
Cell Name: naive B cell (CL0000788)
Fold Change: 0.24
Marker Score: 210
Cell Name: plasmacytoid dendritic cell (CL0000784)
Fold Change: 0.23
Marker Score: 121
Cell Name: pre-B-I cell (CL0000956)
Fold Change: 0.19
Marker Score: 49
Cell Name: mature B cell (CL0000785)
Fold Change: 0.18
Marker Score: 134
Cell Name: Unknown (CL0000003)
Fold Change: 0.18
Marker Score: 563
Cell Name: IgA plasmablast (CL0000984)
Fold Change: 0.17
Marker Score: 45
Cell Name: IgG plasmablast (CL0000982)
Fold Change: 0.15
Marker Score: 42
Cell Name: natural killer cell (CL0000623)
Fold Change: 0.15
Marker Score: 191
Cell Name: transitional stage B cell (CL0000818)
Fold Change: 0.14
Marker Score: 49
Cell Name: IgM plasma cell (CL0000986)
Fold Change: 0.14
Marker Score: 48
Cell Name: CD4-positive, alpha-beta T cell (CL0000624)
Fold Change: 0.12
Marker Score: 276
Cell Name: IgA plasma cell (CL0000987)
Fold Change: 0.12
Marker Score: 103
Cell Name: platelet (CL0000233)
Fold Change: 0.1
Marker Score: 48
Cell Name: erythrocyte (CL0000232)
Fold Change: 0.09
Marker Score: 50
Cell Name: CD8-positive, alpha-beta T cell (CL0000625)
Fold Change: 0.08
Marker Score: 133
Cell Name: endothelial cell of lymphatic vessel (CL0002138)
Fold Change: 0.08
Marker Score: 50
Cell Name: IgG plasma cell (CL0000985)
Fold Change: 0.07
Marker Score: 33
Cell Name: unswitched memory B cell (CL0000970)
Fold Change: 0.07
Marker Score: 44
Cell Name: gamma-delta T cell (CL0000798)
Fold Change: 0.07
Marker Score: 46
Cell Name: immature innate lymphoid cell (CL0001082)
Fold Change: 0.07
Marker Score: 139
Cell Name: immature B cell (CL0000816)
Fold Change: 0.07
Marker Score: 45
Cell Name: activated CD4-positive, alpha-beta T cell (CL0000896)
Fold Change: 0.07
Marker Score: 49
Cell Name: dendritic cell (CL0000451)
Fold Change: 0.07
Marker Score: 46
Cell Name: memory B cell (CL0000787)
Fold Change: 0.07
Marker Score: 50
Cell Name: CD16-positive, CD56-dim natural killer cell, human (CL0000939)
Fold Change: 0.06
Marker Score: 45
Cell Name: classical monocyte (CL0000860)
Fold Change: 0.06
Marker Score: 235
Cell Name: effector CD8-positive, alpha-beta T cell (CL0001050)
Fold Change: 0.06
Marker Score: 47
Cell Name: mucosal invariant T cell (CL0000940)
Fold Change: 0.05
Marker Score: 47
Cell Name: double negative T regulatory cell (CL0011024)
Fold Change: 0.05
Marker Score: 49
Cell Name: CD4-positive helper T cell (CL0000492)
Fold Change: 0.05
Marker Score: 50
Cell Name: stromal cell (CL0000499)
Fold Change: 0.04
Marker Score: 45
Cell Name: B-2 B cell (CL0000822)
Fold Change: 0.04
Marker Score: 45
Cell Name: class switched memory B cell (CL0000972)
Fold Change: 0.04
Marker Score: 34
Cell Name: plasmablast (CL0000980)
Fold Change: 0.03
Marker Score: 45
Cell Name: naive thymus-derived CD4-positive, alpha-beta T cell (CL0000895)
Fold Change: 0.03
Marker Score: 44
Cell Name: double-positive, alpha-beta thymocyte (CL0000809)
Fold Change: 0.03
Marker Score: 50
Cell Name: small pre-B-II cell (CL0000954)
Fold Change: 0.02
Marker Score: 26
Cell Name: CD38-negative naive B cell (CL0002102)
Fold Change: 0.02
Marker Score: 41
Cell Name: large pre-B-II cell (CL0000957)
Fold Change: 0.02
Marker Score: 48
Cell Name: B-1 B cell (CL0000819)
Fold Change: 0.02
Marker Score: 27
Cell Name: CD14-positive monocyte (CL0001054)
Fold Change: 0.01
Marker Score: 37
Cell Name: non-classical monocyte (CL0000875)
Fold Change: 0.01
Marker Score: 34
Cell Name: neuron (CL0000540)
Fold Change: 0.01
Marker Score: 55
Cell Name: blood cell (CL0000081)
Fold Change: 0.01
Marker Score: 92
Cell Name: alveolar macrophage (CL0000583)
Fold Change: 0
Marker Score: 49
Cell Name: CD14-positive, CD16-negative classical monocyte (CL0002057)
Fold Change: 0
Marker Score: 102
Cell Name: mature alpha-beta T cell (CL0000791)
Fold Change: 0
Marker Score: 66
Cell Name: L2/3-6 intratelencephalic projecting glutamatergic neuron (CL4023040)
Fold Change: 0
Marker Score: 48

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Marker Score to the Marker Score Threshold, indicating how much the gene expression has changed compared to a baseline.
Marker Score: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.

Other Information

Description

**Key Characteristics** IGKV2D 40 is a kappa light chain variable region gene, which is a critical component of the B cell receptor (BCR) complex. The gene is characterized by its involvement in several key immune pathways, including: 1. **Complement activation**: IGKV2D 40 is involved in the classical pathway of complement activation, which is a critical mechanism for eliminating pathogens from the body. 2. **Phagocytosis**: The gene is also involved in phagocytosis, a process by which immune cells engulf and eliminate pathogens. 3. **Immune cell interactions**: IGKV2D 40 regulates interactions between immune cells, including T cells and dendritic cells, which is essential for coordinating an effective immune response. **Pathways and Functions** IGKV2D 40 is involved in several key pathways and functions, including: 1. **Adaptive immune system**: IGKV2D 40 is a component of the B cell receptor complex, which is critical for the adaptive immune response. 2. **Anti-inflammatory response**: The gene is involved in anti-inflammatory responses, particularly in the context of Leishmania parasite infection. 3. **Antigen presentation**: IGKV2D 40 is involved in antigen presentation, which is the process by which immune cells present antigens to T cells, triggering an immune response. 4. **Regulation of immune cell activity**: The gene regulates the activity of immune cells, including T cells and dendritic cells, which is essential for coordinating an effective immune response. **Clinical Significance** IGKV2D 40 has significant clinical implications, particularly in the context of Leishmania parasite infection. The gene's involvement in classical antibody-mediated complement activation and phagocytosis makes it a potential target for therapeutic interventions. Additionally, the gene's role in regulating immune cell interactions and anti-inflammatory responses makes it a potential target for the treatment of autoimmune diseases. Furthermore, IGKV2D 40's involvement in the adaptive immune system and antigen presentation makes it a potential target for the development of vaccines and immunotherapies. Overall, further research is needed to fully understand the clinical significance of IGKV2D 40 and its potential as a therapeutic target. **Implications for SARS and Leishmania Infections** IGKV2D 40's involvement in phagocytosis and antigen presentation makes it a potential target for the treatment of SARS and Leishmania infections. The gene's role in regulating immune cell interactions and anti-inflammatory responses also makes it a potential target for the treatment of autoimmune diseases associated with these infections. In the context of SARS, IGKV2D 40's involvement in phagocytosis and antigen presentation makes it a potential target for the development of therapeutic interventions. The gene's role in regulating immune cell interactions and anti-inflammatory responses also makes it a potential target for the treatment of autoimmune diseases associated with SARS. In the context of Leishmania infections, IGKV2D 40's involvement in classical antibody-mediated complement activation and phagocytosis makes it a potential target for the development of therapeutic interventions. The gene's role in regulating immune cell interactions and anti-inflammatory responses also makes it a potential target for the treatment of autoimmune diseases associated with Leishmania infections. **Potential Therapeutic Interventions** IGKV2D 40's involvement in various immune pathways makes it a potential target for the development of therapeutic interventions. Some potential therapeutic interventions include: 1. **Complement inhibitors**: Complement inhibitors could be used to target IGKV2D 40 and inhibit classical antibody-mediated complement activation. 2. **Phagocytosis inhibitors**: Phagocytosis inhibitors could be used to target IGKV2D 40 and inhibit phagocytosis. 3. **Immunomodulatory therapies**: Immunomodulatory therapies could be used to target IGKV2D 40 and regulate immune cell interactions and anti-inflammatory responses. 4. **Vaccines and immunotherapies**: Vaccines and immunotherapies could be developed to target IGKV2D 40 and stimulate an effective immune response against pathogens. Overall, further research is needed to fully understand the clinical significance of IGKV2D 40 and its potential as a therapeutic target.

Disclaimer: This summary is generated by an AI language model and may contain inaccuracies or hallucinations. However, it is cross-referenced with curated gene expression data from major biological sources. Please verify the information before use.

Database document:

This is a preview of the gene's schema. Only a few entries are kept for 'singleCellExpressions,' 'mRNAExpressions,' and other large data arrays for visualization purposes. You can zoom in with the mouse wheel for a closer view, and the text will adjust automatically if necessary. For the full schema, download it here.